{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:00:05Z","timestamp":1794492005165,"version":"4.9.1"},"reference-count":85,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDRR"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Peptides represent a class of natural molecules with diverse physiological functions, including\nhormone regulation, neurotransmission, and immune modulation. In recent years, peptide-\nbased therapeutics have gained significant attention in pharmaceutical research and development\ndue to their high specificity, efficacy, and relatively low toxicity. This review provides an\noverview of the current landscape of peptide drug development, highlighting the challenges faced\nin their formulation and delivery and the innovative strategies employed to overcome these hurdles.\nThe review explores the wide range of applications of peptide drugs in treating various diseases,\nincluding HIV, multiple sclerosis, osteoporosis, chronic pain, diabetes, and cancer. Examples\nof FDA-approved peptide drugs and ongoing clinical trials are presented, showcasing the\ncontinuous advancements in peptide-based therapeutics across different therapeutic areas. This review\nunderscores the promising potential of peptide drugs as targeted and effective treatments for\na multitude of medical conditions, offering improved therapeutic outcomes and enhanced patient\ncare.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0125899775295960240406073630","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T06:20:08Z","timestamp":1713507608000},"page":"381-394","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Peptide Drugs: Current Status and it's Applications in the Treatment of\nVarious Diseases"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-0664","authenticated-orcid":true,"given":"Chandni","family":"Chandarana","sequence":"first","affiliation":[{"name":"Department of Quality Assurance, SSR College of Pharmacy, Sayli Road, Silvassa, U.T of Dadra Nagar and Haveli,\n396230, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Juwarwala","sequence":"additional","affiliation":[{"name":"Department of Quality Assurance, SSR College of Pharmacy, Sayli Road, Silvassa, U.T of Dadra Nagar and Haveli,\n396230, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravi","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Quality Assurance, SSR College of Pharmacy, Sayli Road, Silvassa, U.T of Dadra Nagar and Haveli,\n396230, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushree","family":"Bose","sequence":"additional","affiliation":[{"name":"Department of Quality Assurance, SSR College of Pharmacy, Sayli Road, Silvassa, U.T of Dadra Nagar and Haveli,\n396230, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/B978-0-323-85682-9.00001-5","volume":"1","author":"Hemanth Kumar N.K.","year":"2023","unstructured":"Hemanth Kumar N.K.; Poornachandra Rao K.; Somashekaraiah R.; Jagannath S.; Sreenivasa M.Y.; Recent advances and challenges in peptide drug development. Antimicrobial Peptides  2023,1,297-310","journal-title":"Antimicrobial Peptides"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"100079","DOI":"10.1016\/j.medidd.2020.100079","volume":"9","author":"Ganesh A.N.","year":"2021","unstructured":"Ganesh A.N.; Heusser C.; Garad S.; S\u00e1nchez-F\u00e9lix M.V.; Patient-centric design for peptide delivery: Trends in routes of administration and advancement in drug delivery technologies. Med Drug Discov  2021,9,100079","journal-title":"Med Drug Discov"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","volume":"26","author":"Lau J.L.","year":"2018","unstructured":"Lau J.L.; Dunn M.K.; Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem  2018,26(10),2700-2707","journal-title":"Bioorg Med Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"Fosgerau K.","year":"2015","unstructured":"Fosgerau K.; Hoffmann T.; Peptide therapeutics: Current status and future directions. Drug Discov Today  2015,20(1),122-128","journal-title":"Drug Discov Today"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"102124","DOI":"10.1016\/j.jddst.2020.102124","volume":"61","author":"Cao S.","year":"2021","unstructured":"Cao S.; Lv Z.; Guo S.; Jiang G.; Liu H.; An update - Prolonging the action of protein and peptide drugs. J Drug Deliv Sci Technol  2021,61,102124","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/v9100281","volume":"9","author":"Chupradit K.","year":"2017","unstructured":"Chupradit K.; Moonmuang S.; Nangola S.; Kitidee K.; Yasamut U.; Mougel M.; Tayapiwatana C.; Current peptide and protein candidates challenging HIV therapy beyond the vaccine era. Viruses  2017,9(10),281","journal-title":"Viruses"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"100545","DOI":"10.1016\/j.ijans.2023.100545","volume":"18","author":"Mutaru A.M.","year":"2023","unstructured":"Mutaru A.M.; Ibrahim A.; Wumpini Osuman A-N.; Atanga Agana T.; Sukerazu Alhassan A.; Knowledge, attitude and clinical practice regarding HIV\/AIDS among trainee nurses in north-eastern corridor, Ghana. Int J Afr Nurs Sci  2023,18,100545","journal-title":"Int J Afr Nurs Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"a006841","DOI":"10.1101\/cshperspect.a006841","volume":"1","author":"Sharp P.M.","year":"2011","unstructured":"Sharp P.M.; Hahn B.H.; Origins of HIV and the AIDS Pandemic. Cold Spring Harb Perspect Med  2011,1(1),a006841","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"106792","DOI":"10.1016\/j.ijantimicag.2023.106792","volume":"61","author":"Ce\u00f1a-Diez R.","year":"2023","unstructured":"Ce\u00f1a-Diez R.; Narayanan A.; Ray S.; van de Klundert M.; Rodriguez J.E.; Nilvebrant J.; Nygren P.\u00c5.; V\u00e9gv\u00e1ri \u00c1.; van Domselaar R.; S\u00f6nnerborg A.; Naturally occurring dipeptide from elite controllers with dual anti-HIV-1 mechanism. Int J Antimicrob Agents  2023,61(5),106792","journal-title":"Int J Antimicrob Agents"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bioactmat.2016.09.004","volume":"1","author":"Shi S.","year":"2016","unstructured":"Shi S.; Nguyen P.K.; Cabral H.J.; Diez-Barroso R.; Derry P.J.; Kanahara S.M.; Kumar V.A.; Development of peptide inhibitors of HIV transmission. Bioact Mater  2016,1(2),109-121","journal-title":"Bioact Mater"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/cbdd.12055","volume":"81","author":"Craik D.J.","year":"2013","unstructured":"Craik D.J.; Fairlie D.P.; Liras S.; Price D.; The future of peptide-based drugs. Chem Biol Drug Des  2013,81(1),136-147","journal-title":"Chem Biol Drug Des"},{"key":"ref=12","first-page":"49","volume":"19","author":"Akbulut E.O.","year":"2012","unstructured":"Akbulut E.O.; Protein-peptide interactions revolutionize drug development. Binding Protein  2012,19,49","journal-title":"Binding Protein"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.biotechadv.2014.07.006","volume":"32","author":"Choonara B.F.","year":"2014","unstructured":"Choonara B.F.; Choonara Y.E.; Kumar P.; Bijukumar D.; du Toit L.C.; Pillay V.; A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv  2014,32(7),1269-1282","journal-title":"Biotechnol Adv"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/TCRM.S1962","volume":"4","author":"Kitchen C.","year":"2008","unstructured":"Kitchen C.; Nu\u00f1o M.; Kitchen S.G.; Krogstad P.; Enfuvirtide antiretroviral therapy in HIV-1 infection. Ther Clin Risk Manag  2008,4(2),433-439","journal-title":"Ther Clin Risk Manag"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","volume":"91","author":"Wild C.T.","year":"1994","unstructured":"Wild C.T.; Shugars D.C.; Greenwell T.K.; McDanal C.B.; Matthews T.J.; Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA  1994,91(21),9770-9774","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1128\/jvi.69.6.3771-3777.1995","volume":"69","author":"Chen C.H.","year":"1995","unstructured":"Chen C.H.; Matthews T.J.; McDanal C.B.; Bolognesi D.P.; Greenberg M.L.; A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol  1995,69(6),3771-3777","journal-title":"J Virol"},{"key":"ref=17","unstructured":"Drugbank   Available from:  https:\/\/go.drugbank.com\/drugs\/DB00109 (cited on 1 July 2023)."},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"9254","DOI":"10.1073\/pnas.83.23.9254","volume":"83","author":"Pert C.B.","year":"1986","unstructured":"Pert C.B.; Hill J.M.; Ruff M.R.; Berman R.M.; Robey W.G.; Arthur L.O.; Ruscetti F.W.; Farrar W.L.; Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Natl Acad Sci USA  1986,83(23),9254-9258","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1089\/0889222041725181","volume":"20","author":"Alam S.M.","year":"2004","unstructured":"Alam S.M.; Paleos C.A.; Liao H.X.; Scearce R.; Robinson J.; Haynes B.F.; An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. AIDS Res Hum Retroviruses  2004,20(8),836-845","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/00003495-200059030-00002","volume":"59","author":"Weinstock-Guttman B.","year":"2000","unstructured":"Weinstock-Guttman B.; Jacobs L.D.; What is new in the treatment of multiple sclerosis? Drugs  2000,59(3),401-410","journal-title":"Drugs"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"Ebers G.C.","year":"1998","unstructured":"Ebers G.C.; Randomised double-blind placebo-controlled study of interferon \u03b2-1a in relapsing\/remitting multiple sclerosis. Lancet  1998,352(9139),1498-1504","journal-title":"Lancet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.3390\/molecules26175227","volume":"26","author":"Del Gatto A.","year":"2021","unstructured":"Del Gatto A.; Saviano M.; Zaccaro L.; An overview of peptide-based molecules as potential drug candidates for multiple sclerosis. Molecules  2021,26(17),5227","journal-title":"Molecules"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/14737175.2019.1632192","volume":"19","author":"Baldassari L.E.","year":"2019","unstructured":"Baldassari L.E.; Feng J.; Clayton B.L.L.; Oh S.H.; Sakaie K.; Tesar P.J.; Wang Y.; Cohen J.A.; Developing therapeutic strategies to promote myelin repair in multiple sclerosis. Expert Rev Neurother  2019,19(10),997-1013","journal-title":"Expert Rev Neurother"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"105441","DOI":"10.1016\/j.phrs.2021.105441","volume":"167","author":"Rayatpour A.","year":"2021","unstructured":"Rayatpour A.; Javan M.; Targeting the brain lesions using peptides: A review focused on the possibility of targeted drug delivery to multiple sclerosis lesions. Pharmacol Res  2021,167,105441","journal-title":"Pharmacol Res"},{"key":"ref=25","unstructured":"Multiple sclerosis trust.  Avaiable from:  https:\/\/www.mstrust.org.uk\/a-z\/atx-ms-1467 [cited 2023 April 23]."},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s13311-015-0379-1","volume":"12","author":"Yuan R.","year":"2015","unstructured":"Yuan R.; Wang B.; Lu W.; Maeda Y.; Dowling P.; A distinct region in erythropoietin that induces immuno\/inflammatory modulation and tissue protection. Neurotherapeutics  2015,12(4),850-861","journal-title":"Neurotherapeutics"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nri2153","volume":"7","author":"Miller S.D.","year":"2007","unstructured":"Miller S.D.; Turley D.M.; Podojil J.R.; Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol  2007,7(9),665-677","journal-title":"Nat Rev Immunol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1073\/pnas.87.4.1337","volume":"87","author":"Kumar V.","year":"1990","unstructured":"Kumar V.; Urban J.L.; Horvath S.J.; Hood L.; Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis. Proc Natl Acad Sci USA  1990,87(4),1337-1341","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1073\/pnas.96.2.634","volume":"96","author":"Aharoni R.","year":"1999","unstructured":"Aharoni R.; Teitelbaum D.; Arnon R.; Sela M.; Copolymer 1 acts against the immunodominant epitope 82\u2013100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci USA  1999,96(2),634-639","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.4049\/jimmunol.167.5.2688","volume":"167","author":"Ruiz P.J.","year":"2001","unstructured":"Ruiz P.J.; DeVoss J.J.; Nguyen L.V.T.; Fontoura P.P.; Hirschberg D.L.; Mitchell D.J.; Garcia K.C.; Steinman L.; Immunomodulation of experimental autoimmune encephalomyelitis with ordered peptides based on MHC-TCR binding motifs. J Immunol  2001,167(5),2688-2693","journal-title":"J Immunol"},{"key":"ref=31","first-page":"CD004678","author":"Munari L.","year":"2004","unstructured":"Munari L.; Lovati R.; Boiko A.; Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev  2004(1),CD004678","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0952-7915(93)90054-V","volume":"5","author":"Jenkins M.K.","year":"1993","unstructured":"Jenkins M.K.; Johnson J.G.; Molecules involved in T-cell costimulation. Curr Opin Immunol  1993,5(3),361-367","journal-title":"Curr Opin Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0167-5699(94)90080-9","volume":"15","author":"June C.H.","year":"1994","unstructured":"June C.H.; Bluestone J.A.; Nadler L.M.; Thompson C.B.; The B7 and CD28 receptor families. Immunol Today  1994,15(7),321-331","journal-title":"Immunol Today"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2174\/1381612023393170","volume":"8","author":"Iyer S.","year":"2002","unstructured":"Iyer S.; Lahana R.; Buelow R.; Rational design and development of RDP58. Curr Pharm Des  2002,8(24),2217-2229","journal-title":"Curr Pharm Des"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/00001756-200107030-00016","volume":"12","author":"Liu Y.","year":"2001","unstructured":"Liu Y.; Zhu B.; Luo L.; Li P.; Paty D.W.; Cynader M.S.; Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport  2001,12(9),1841-1845","journal-title":"Neuroreport"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0165-5728(03)00132-2","volume":"139","author":"Liu Y.","year":"2003","unstructured":"Liu Y.; Zhu B.; Wang X.; Luo L.; Li P.; Paty D.W.; Cynader M.S.; Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J Neuroimmunol  2003,139(1-2),27-35","journal-title":"J Neuroimmunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/BF03401995","volume":"5","author":"Cuturi M.C.","year":"1999","unstructured":"Cuturi M.C.; Christoph F.; Woo J.; Iyer S.; Brouard S.; Heslan J.M.; Pignon P.; Soulillou J.P.; Buelow R.; RDP1258, a new rationally designed immunosuppressive peptide, prolongs allograft survival in rats: Analysis of its mechanism of action. Mol Med  1999,5(12),820-832","journal-title":"Mol Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1074\/jbc.273.5.2692","volume":"273","author":"Iyer S.","year":"1998","unstructured":"Iyer S.; Woo J.; Cornejo M.C.; Gao L.; McCoubrey W.; Maines M.; Buelow R.; Characterization and biological significance of immunosuppressive peptide D2702.75-84(E --> V) binding protein. Isolation of heme oxygenase-1. J Biol Chem  1998,273(5),2692-2697","journal-title":"J Biol Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.taap.2008.01.038","volume":"229","author":"Brodsky B.","year":"2008","unstructured":"Brodsky B.; Erlangerrosengarten A.; Proscura E.; Shapira E.; Wormser U.; From topical antidote against skin irritants to a novel counter-irritating and anti-inflammatory peptide. Toxicol Appl Pharmacol  2008,229(3),342-350","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaut.2010.03.004","volume":"35","author":"Shapira E.","year":"2010","unstructured":"Shapira E.; Brodsky B.; Proscura E.; Nyska A.; Erlanger-Rosengarten A.; Wormser U.; Amelioration of experimental autoimmune encephalitis by novel peptides: Involvement of T regulatory cells. J Autoimmun  2010,35(1),98-106","journal-title":"J Autoimmun"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJM199208273270908","volume":"327","author":"Wood A.J.J.","year":"1992","unstructured":"Wood A.J.J.; Riggs B.L.; Melton L.J.; The prevention and treatment of osteoporosis. N Engl J Med  1992,327(9),620-627","journal-title":"N Engl J Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","volume":"377","author":"Rachner T.D.","year":"2011","unstructured":"Rachner T.D.; Khosla S.; Hofbauer L.C.; Osteoporosis: Now and the future. Lancet  2011,377(9773),1276-1287","journal-title":"Lancet"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"Klibanski A.","year":"2001","unstructured":"Klibanski A.; Adams-Campbell L.; Bassford T.; Blair S.N.; Boden S.D.; Dickersin K.; Osteoporosis prevention, diagnosis, and therapy. JAMA  2001,285(6),785-795","journal-title":"JAMA"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2106\/JBJS.I.00919","volume":"92","author":"Unnanuntana A.","year":"2010","unstructured":"Unnanuntana A.; Gladnick B.P.; Donnelly E.; Lane J.M.; The assessment of fracture risk. J Bone Joint Surg Am  2010,92(3),743-753","journal-title":"J Bone Joint Surg Am"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/pmj.79.929.133","volume":"79","author":"Christodoulou C.","year":"2003","unstructured":"Christodoulou C.; Cooper C.; What is osteoporosis? Postgrad Med J  2003,79(929),133-138","journal-title":"Postgrad Med J"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/10408398.2020.1836606","volume":"62","author":"Chen Y.","year":"2022","unstructured":"Chen Y.; Chen J.; Chen J.; Yu H.; Zheng Y.; Zhao J.; Zhu J.; Recent advances in seafood bioactive peptides and their potential for managing osteoporosis. Crit Rev Food Sci Nutr  2022,62(5),1187-1203","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"Cosman F.","year":"2014","unstructured":"Cosman F.; de Beur S.J.; LeBoff M.S.; Lewiecki E.M.; Tanner B.; Randall S.; Lindsay R.; Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int  2014,25(10),2359-2381","journal-title":"Osteoporos Int"},{"key":"ref=48","first-page":"92","volume":"43","author":"Tu K.N.","year":"2018","unstructured":"Tu K.N.; Lie J.D.; Wan C.K.V.; Cameron M.; Austel A.G.; Nguyen J.K.; Van K.; Hyun D.; Osteoporosis: A review of treatment options. PandT  2018,43(2),92-104","journal-title":"PandT"},{"key":"ref=49","first-page":"117","volume":"4","author":"Masi L.","year":"2007","unstructured":"Masi L.; Brandi M.L.; Calcitonin and calcitonin receptors. Clin Cases Miner Bone Metab  2007,4(2),117-122","journal-title":"Clin Cases Miner Bone Metab"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ckj\/sfv011","volume":"8","author":"Felsenfeld A.J.","year":"2015","unstructured":"Felsenfeld A.J.; Levine B.S.; Calcitonin, the forgotten hormone: Does it deserve to be forgotten? Clin Kidney J  2015,8(2),180-187","journal-title":"Clin Kidney J"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1073\/pnas.64.2.771","volume":"64","author":"Niall H.D.","year":"1969","unstructured":"Niall H.D.; Keutmann H.T.; Copp D.H.; Potts J.T.; Amino acid sequence of salmon ultimobranchial calcitonin. Proc Natl Acad Sci USA  1969,64(2),771-778","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"24193","DOI":"10.1074\/jbc.M603528200","volume":"281","author":"Andreotti G.","year":"2006","unstructured":"Andreotti G.; M\u00e9ndez B.L.; Amodeo P.; Morelli M.A.C.; Nakamuta H.; Motta A.; Structural determinants of salmon calcitonin bioactivity: The role of the Leu-based amphipathic \u03b1-helix. J Biol Chem  2006,281(34),24193-24203","journal-title":"J Biol Chem"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1172\/JCI112584","volume":"78","author":"Nicholson G.C.","year":"1986","unstructured":"Nicholson G.C.; Moseley J.M.; Sexton P.M.; Mendelsohn F.A.; Martin T.J.; Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest  1986,78(2),355-360","journal-title":"J Clin Invest"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"Neer R.M.","year":"2001","unstructured":"Neer R.M.; Arnaud C.D.; Zanchetta J.R.; Prince R.; Gaich G.A.; Reginster J.Y.; Hodsman A.B.; Eriksen E.F.; Ish-Shalom S.; Genant H.K.; Wang O.; Mellstr\u00f6m D.; Oefjord E.S.; Marcinowska-Suchowierska E.; Salmi J.; Mulder H.; Halse J.; Sawicki A.Z.; Mitlak B.H.; Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med  2001,344(19),1434-1441","journal-title":"N Engl J Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0149-2918(04)90128-2","volume":"26","author":"Quattrocchi E.","year":"2004","unstructured":"Quattrocchi E.; Kourlas H.; Teriparatide: A review. Clin Ther  2004,26(6),841-854","journal-title":"Clin Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"CMT-S2358.","DOI":"10.4137\/CMT.S2358","volume":"3","author":"Inderjeeth CA","year":"2011","unstructured":"Inderjeeth CA; Chan K; Glendenning P; Teriparatide: Its use in the treatment of osteoporosis.  Clinical Medicine Insights: Therapeutics  2011,3,CMT-S2358.","journal-title":"Clinical Medicine Insights: Therapeutics"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/nedt.2007.3.1.69","volume":"3","author":"McGivern J.G.","year":"2007","unstructured":"McGivern J.G.; Ziconotide: A review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat  2007,3(1),69-85","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40122-018-0097-6","volume":"7","author":"Jones M.R.","year":"2018","unstructured":"Jones M.R.; Viswanath O.; Peck J.; Kaye A.D.; Gill J.S.; Simopoulos T.T.; A brief history of the opioid epidemic and strategies for pain medicine. Pain Ther  2018,7(1),13-21","journal-title":"Pain Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1097\/j.pain.0000000000001262","volume":"159","author":"Drieu la Rochelle A.","year":"2018","unstructured":"Drieu la Rochelle A.; Guillemyn K.; Dumitrascuta M.; Martin C.; Utard V.; Quillet R.; Schneider S.; Daubeuf F.; Willemse T.; Mampuys P.; Maes B.U.W.; Frossard N.; Bihel F.; Spetea M.; Simonin F.; Ballet S.; A bifunctional-biased mu-opioid agonist\u2013neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects. Pain  2018,159(9),1705-1718","journal-title":"Pain"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0196-9781(85)90371-7","volume":"6","author":"Basso N.","year":"1985","unstructured":"Basso N.; Marcelli M.; Ginaldi A.; De Marco M.; Intrathecal dermorphine in postoperative analgesia. Peptides  1985,6(Suppl. 3),177-179","journal-title":"Peptides"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","volume":"20","author":"Muttenthaler M.","year":"2021","unstructured":"Muttenthaler M.; King G.F.; Adams D.J.; Alewood P.F.; Trends in peptide drug discovery. Nat Rev Drug Discov  2021,20(4),309-325","journal-title":"Nat Rev Drug Discov"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"8825","DOI":"10.3390\/ijms21228825","volume":"21","author":"Tyagi A.","year":"2020","unstructured":"Tyagi A.; Daliri E.B.M.; Kwami Ofosu F.; Yeon S.J.; Oh D.H.; Food-derived opioid peptides in human health: A review. Int J Mol Sci  2020,21(22),8825","journal-title":"Int J Mol Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"22353","DOI":"10.1073\/pnas.1908662116","volume":"116","author":"Dekan Z.","year":"2019","unstructured":"Dekan Z.; Sianati S.; Yousuf A.; Sutcliffe K.J.; Gillis A.; Mallet C.; Singh P.; Jin A.H.; Wang A.M.; Mohammadi S.A.; Stewart M.; Ratnayake R.; Fontaine F.; Lacey E.; Piggott A.M.; Du Y.P.; Canals M.; Sessions R.B.; Kelly E.; Capon R.J.; Alewood P.F.; Christie M.J.; A tetrapeptide class of biased analgesics from an Australian fungus targets the \u00b5-opioid receptor. Proc Natl Acad Sci USA  2019,116(44),22353-22358","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"Sun H.","year":"2022","unstructured":"Sun H.; Saeedi P.; Karuranga S.; Pinkepank M.; Ogurtsova K.; Duncan B.B.; Stein C.; Basit A.; Chan J.C.N.; Mbanya J.C.; Pavkov M.E.; Ramachandaran A.; Wild S.H.; James S.; Herman W.H.; Zhang P.; Bommer C.; Kuo S.; Boyko E.J.; Magliano D.J.; IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract  2022,183,109119","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2337\/diab.28.12.1039","volume":"28","year":"1979","unstructured":"Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes  1979,28(12),1039-1057","journal-title":"Diabetes"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.46300\/91011.2022.16.1","volume":"16","author":"Bhuyan M.H.","year":"2022","unstructured":"Bhuyan M.H.; A modern review of the non-invasive continuous blood glucose measuring devices and techniques for remote patient monitoring system. Int J Biol Biomed Eng  2022,16(2),1-21","journal-title":"Int J Biol Biomed Eng"},{"key":"ref=67","year":"2011","unstructured":"Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: Abbreviated report of a WHO consultation  2011","journal-title":"Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: Abbreviated report of a WHO consultation"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1021\/acs.nanolett.1c00832","volume":"21","author":"Shahriar S.M.S.","year":"2021","unstructured":"Shahriar S.M.S.; An J.M.; Hasan M.N.; Surwase S.S.; Kim Y.C.; Lee D.Y.; Cho S.; Lee Y.; Plasmid DNA nanoparticles for nonviral oral gene therapy. Nano Lett  2021,21(11),4666-4675","journal-title":"Nano Lett"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.addr.2016.02.011","volume":"106","author":"Lakkireddy H.R.","year":"2016","unstructured":"Lakkireddy H.R.; Urmann M.; Besenius M.; Werner U.; Haack T.; Brun P.; Ali\u00e9 J.; Illel B.; Hortala L.; Vogel R.; Bazile D.; Oral delivery of diabetes peptides \u2014 Comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context. Adv Drug Deliv Rev  2016,106(Pt B),196-222","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13300-014-0061-3","volume":"5","author":"Craddy P.","year":"2014","unstructured":"Craddy P.; Palin H.J.; Johnson K.I.; Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: A systematic review and mixed treatment comparison. Diabetes Ther  2014,5(1),1-41","journal-title":"Diabetes Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40261-019-00826-0","volume":"39","author":"Lyseng-Williamson K.A.","year":"2019","unstructured":"Lyseng-Williamson K.A.; Glucagon-like peptide-1 receptor analogues in type 2 diabetes: Their use and differential features. Clin Drug Investig  2019,39(8),805-819","journal-title":"Clin Drug Investig"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1124\/pr.115.010629","volume":"67","author":"Hay D.L.","year":"2015","unstructured":"Hay D.L.; Chen S.; Lutz T.A.; Parkes D.G.; Roth J.D.; Amylin: Pharmacology, physiology, and clinical potential. Pharmacol Rev  2015,67(3),564-600","journal-title":"Pharmacol Rev"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/dom.12504","volume":"17","author":"Riddle M.C.","year":"2015","unstructured":"Riddle M.C.; Yuen K.C.J.; de Bruin T.W.; Herrmann K.; Xu J.; \u00d6hman P.; Kolterman O.G.; Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes. Diabetes Obes Metab  2015,17(9),904-907","journal-title":"Diabetes Obes Metab"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"Lau J.","year":"2015","unstructured":"Lau J.; Bloch P.; Sch\u00e4ffer L.; Pettersson I.; Spetzler J.; Kofoed J.; Madsen K.; Knudsen L.B.; McGuire J.; Steensgaard D.B.; Strauss H.M.; Gram D.X.; Knudsen S.M.; Nielsen F.S.; Thygesen P.; Reedtz-Runge S.; Kruse T.; Sch\u00e4ffer Let al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem  2015,58(18),7370-7380","journal-title":"J Med Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14831","volume":"25","author":"De Block C.","year":"2023","unstructured":"De Block C.; Bailey C.; Wysham C.; Hemmingway A.; Allen S.E.; Peleshok J.; Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes Obes Metab  2023,25(1),3-17","journal-title":"Diabetes Obes Metab"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"Coskun T.","year":"2018","unstructured":"Coskun T.; Sloop K.W.; Loghin C.; Alsina-Fernandez J.; Urva S.; Bokvist K.B.; Cui X.; Briere D.A.; Cabrera O.; Roell W.C.; Kuchibhotla U.; Moyers J.S.; Benson C.T.; Gimeno R.E.; D\u2019Alessio D.A.; Haupt A.; LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab  2018,18,3-14","journal-title":"Mol Metab"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s11095-008-9661-9","volume":"25","author":"Anand P.","year":"2008","unstructured":"Anand P.; Kunnumakara A.B.; Sundaram C.; Harikumar K.B.; Tharakan S.T.; Lai O.S.; Sung B.; Aggarwal B.B.; Cancer is a preventable disease that requires major lifestyle changes. Pharm Res  2008,25(9),2097-2116","journal-title":"Pharm Res"},{"key":"ref=78","author":"Agarwal S.P.","year":"2002","unstructured":"Agarwal S.P.; Rao Y.N.; Gupta S.;  Fifty years of cancer control in India Directorate general of health services, Ministry of health and family welfare  2002","journal-title":"Fifty years of cancer control in India Directorate general of health services, Ministry of health and family welfare"},{"key":"ref=79","unstructured":"What is Cancer?  Available from:  https:\/\/www.cancer.gov\/aboutcancer\/understanding\/what-is-cancer [cited 2023 May 03]."},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1039\/D0CS00556H","volume":"50","author":"Cooper B.M.","year":"2021","unstructured":"Cooper B.M.; Iegre J.; O\u2019 Donovan D.H.; \u00d6lweg\u00e5rd Halvarsson M.; Spring D.R.; Peptides as a platform for targeted therapeutics for cancer: peptide\u2013drug conjugates (PDCs). Chem Soc Rev  2021,50(3),1480-1494","journal-title":"Chem Soc Rev"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"17745","DOI":"10.1021\/acsami.7b03682","volume":"9","author":"Ruan H.","year":"2017","unstructured":"Ruan H.; Chen X.; Xie C.; Li B.; Ying M.; Liu Y.; Zhang M.; Zhang X.; Zhan C.; Lu W.; Lu W.; Stapled RGD peptide enables glioma-targeted drug delivery by overcoming multiple barriers. ACS Appl Mater Interfaces  2017,9(21),17745-17756","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"Bargh J.D.","year":"2019","unstructured":"Bargh J.D.; Isidro-Llobet A.; Parker J.S.; Spring D.R.; Cleavable linkers in antibody\u2013drug conjugates. Chem Soc Rev  2019,48(16),4361-4374","journal-title":"Chem Soc Rev"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/med.20225","volume":"32","author":"Majumdar S.","year":"2012","unstructured":"Majumdar S.; Siahaan T.J.; Peptide\u2010mediated targeted drug delivery. Med Res Rev  2012,32(3),637-658","journal-title":"Med Res Rev"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"Wang L.","year":"2022","unstructured":"Wang L.; Wang N.; Zhang W.; Cheng X.; Yan Z.; Shao G.; Wang X.; Wang R.; Fu C.; Therapeutic peptides: Current applications and future directions. Signal Transduct Target Ther  2022,7(1),48","journal-title":"Signal Transduct Target Ther"},{"key":"ref=85","unstructured":"Clinical trials.  Available from:  https:\/\/clinicaltrials.gov\/ [cited 2023 May 08]."}],"container-title":["Current Drug Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0125899775295960240406073630","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/229045\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0125899775295960240406073630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T09:48:26Z","timestamp":1727084906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/229045\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0125899775295960240406073630","relation":{},"ISSN":["2589-9775"],"issn-type":[{"value":"2589-9775","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}